AXSM — Axsome Therapeutics Share Price
0.000.00%
Last trade - 00:00- $4.82bn
- $4.69bn
- $385.69m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 84.56 | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 12.5 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -82.91% | ||
| Return on Equity | -231.63% | ||
| Operating Margin | -72.74% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | 50.04 | 270.6 | 385.69 | 622.13 | 1,015.54 | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Axsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company. The Company is engaged in developing and delivering therapies for central nervous system (CNS), conditions that have limited treatment options. The Company's two commercial products and development programs are Auvelity and Sunosi. Auvelity (dextromethorphan-bupropion) is an oral, N-methyl-D-aspartate (NMDA) receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder (MDD). Sunosi (solriamfetol) is an oral medication indicated for the treatment of excessive daytime sleepiness (EDS), in patients with narcolepsy or obstructive sleep apnea. AXS-05 is an oral, investigational NMDA receptor antagonist with multimodal activity under development for the treatment of Alzheimer's disease agitation (AD agitation) and smoking cessation. AXS-07 is an oral, rapidly absorbed, multi-mechanistic, investigational medicine under development for the acute treatment of migraine.
Directors
- Herriot Tabuteau CHM (52)
- Nick Pizzie CFO (46)
- Mark Jacobson COO (37)
- Kevin Laliberte EVP (43)
- Lori Englebert SVP (43)
- Amanda Jones SVP (38)
- Cedric O'Gorman SVP (46)
- Roger Jeffs LED (60)
- Mark Coleman IND (53)
- Mark Saad IND (51)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- January 12th, 2012
- Public Since
- November 19th, 2015
- No. of Shareholders
- 2
- No. of Employees
- 683
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- NASDAQ Global Market
- Shares in Issue
- 48,765,403
- Address
- One World Trade Center, 22Nd Floor, NEW YORK, 10007
- Web
- https://www.axsome.com/
- Phone
- +1 2123323241
- Auditors
- Deloitte & Touche LLP
Upcoming Events for AXSM
Axsome Therapeutics Inc Annual Shareholders Meeting
Q2 2025 Axsome Therapeutics Inc Earnings Release
Similar to AXSM
111
NASDAQ Global Market
ADMA Biologics
NASDAQ Global Market
ANI Pharmaceuticals
NASDAQ Global Market
Aquestive Therapeutics
NASDAQ Global Market
Avadel Pharmaceuticals
NASDAQ Global Market
FAQ
What is the Axsome Therapeutics share price?
As of Today at 19:28 UTC, shares in Axsome Therapeutics are trading at $98.86. This share price information is delayed by 15 minutes.
How has the Axsome Therapeutics share price performed this year?
Shares in Axsome Therapeutics last closed at $98.86 and the price had moved by +36.98% over the past 365 days. In terms of relative price strength the Axsome Therapeutics share price has outperformed the S&P500 Index by +40.5% over the past year.
What are the analyst and broker recommendations for Axsome Therapeutics?
The overall consensus recommendation for Axsome Therapeutics is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Axsome Therapeutics dividend yield?
Axsome Therapeutics does not currently pay a dividend.
Does Axsome Therapeutics pay a dividend?
Axsome Therapeutics does not currently pay a dividend.
When does Axsome Therapeutics next pay dividends?
Axsome Therapeutics does not currently pay a dividend.
How do I buy Axsome Therapeutics shares?
To buy shares in Axsome Therapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Axsome Therapeutics?
As of the previous close price of $98.86, shares in Axsome Therapeutics had a market capitalisation of $4.82bn.
Where are Axsome Therapeutics shares listed?
Here are the trading details for Axsome Therapeutics:
- Country of listing: United States
- Exchange: NMQ
- Ticker Symbol: AXSM
What kind of share is Axsome Therapeutics?
Based on an overall assessment of its quality, value and momentum Axsome Therapeutics is currently classified as a High Flyer. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Axsome Therapeutics share price forecast for 2025?
The analyst consensus target price for shares in Axsome Therapeutics is $176.06. That is 78.09% above the last closing price of $98.86.
Analysts covering Axsome Therapeutics currently have a consensus Earnings Per Share (EPS) forecast of -$3.25 for the next financial year.
Find out moreWhat is the trend in the Axsome Therapeutics share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Axsome Therapeutics. Over the past six months, its share price has outperformed the S&P500 Index by +28.16%.
As of the last closing price of $98.86, shares in Axsome Therapeutics were trading +2.14% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Axsome Therapeutics PE Ratio?
The Axsome Therapeutics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $98.86.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Axsome Therapeutics?
Axsome Therapeutics' management team is headed by:
- Herriot Tabuteau - CHM
- Nick Pizzie - CFO
- Mark Jacobson - COO
- Kevin Laliberte - EVP
- Lori Englebert - SVP
- Amanda Jones - SVP
- Cedric O'Gorman - SVP
- Roger Jeffs - LED
- Mark Coleman - IND
- Mark Saad - IND